AG˹ٷ

STOCK TITAN

[Form 4] Incyte Genomics Inc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

On 26 June 2025, Incyte Corporation (NASDAQ: INCY) filed a Form 4 reporting an insider transaction by Chief Executive Officer and Director William Meury. The filing discloses a grant of 110,630 employee stock options with an exercise price of $70.81 per share. The options vest 25 % after one year, with the remaining 75 % vesting in equal monthly installments over the subsequent three years, and expire on 25 June 2035. After this grant, Meury beneficially owns 110,630 derivative securities, held directly. No purchases or sales of common stock were reported, and the transaction is classified as "A" (acquisition). The document was signed on 30 June 2025.

Il 26 giugno 2025, Incyte Corporation (NASDAQ: INCY) ha presentato un Modulo 4 che riporta una transazione interna da parte del Amministratore Delegato e Direttore William Meury. Il documento rivela una concessione di 110.630 opzioni su azioni per dipendenti con un prezzo di esercizio di 70,81 $ per azione. Le opzioni maturano il 25% dopo un anno, mentre il restante 75% matura in rate mensili uguali nei successivi tre anni, e scadono il 25 giugno 2035. Dopo questa concessione, Meury detiene beneficiariamente 110.630 titoli derivati, posseduti direttamente. Non sono stati segnalati acquisti o vendite di azioni ordinarie, e la transazione è classificata come "A" (acquisizione). Il documento è stato firmato il 30 giugno 2025.

El 26 de junio de 2025, Incyte Corporation (NASDAQ: INCY) presentó un Formulario 4 reportando una transacción interna por parte del Director Ejecutivo y Director William Meury. El informe revela una concesión de 110,630 opciones sobre acciones para empleados con un precio de ejercicio de $70.81 por acción. Las opciones se consolidan en un 25% después de un año, y el 75% restante se consolida en cuotas mensuales iguales durante los siguientes tres años, y expiran el 25 de junio de 2035. Tras esta concesión, Meury posee beneficiosamente 110,630 valores derivados, mantenidos directamente. No se reportaron compras ni ventas de acciones comunes, y la transacción se clasifica como "A" (adquisición). El documento fue firmado el 30 de junio de 2025.

2025� 6� 26�, 인사이트 코퍼레이�(NASDAQ: INCY)은 최고경영� � 이사 윌리� 뮤리� 내부� 거래� 보고하는 Form 4� 제출했습니다. 해당 보고서에� 주당 $70.81� 행사 가격으� 110,630개의 직원 주식매수선택� 부여가 공개되어 있습니다. � 옵션은 1� � 25%가 권리 취득되며, 나머지 75%� 이후 3년간 매월 균등하게 권리 취득되고, 2035� 6� 25�� 만료됩니�. 이번 부� 이후 뮤리� 직접 보유� 110,630개의 파생 증권� 실질 소유하게 됩니�. 보통� 매매� 보고되지 않았으며, 거래� "A"(취득)� 분류되었습니�. 문서� 2025� 6� 30일에 서명되었습니�.

Le 26 juin 2025, Incyte Corporation (NASDAQ : INCY) a déposé un formulaire 4 rapportant une transaction d’initié réalisée par le Directeur Général et Administrateur William Meury. Le document révèle l’attribution de 110 630 options d’achat d’actions pour les employés avec un prix d’exercice de 70,81 $ par action. Les options acquièrent 25 % de leurs droits après un an, le reste des 75 % étant acquis par mensualités égales sur les trois années suivantes, et expirent le 25 juin 2035. Après cette attribution, Meury détient de manière bénéficiaire 110 630 titres dérivés, détenus directement. Aucune acquisition ou vente d’actions ordinaires n’a été signalée, et la transaction est classée « A » (acquisition). Le document a été signé le 30 juin 2025.

Am 26. Juni 2025 reichte die Incyte Corporation (NASDAQ: INCY) ein Formular 4 ein, das eine Insider-Transaktion des Vorstandsvorsitzenden und Direktors William Meury meldet. Die Einreichung offenbart die Gewährung von 110.630 Mitarbeiteraktienoptionen mit einem Ausübungspreis von 70,81 $ pro Aktie. Die Optionen werden zu 25 % nach einem Jahr fällig, die restlichen 75 % werden in gleichen monatlichen Raten über die folgenden drei Jahre fällig und verfallen am 25. Juni 2035. Nach dieser Gewährung besitzt Meury wirtschaftlich 110.630 derivative Wertpapiere, die direkt gehalten werden. Es wurden keine Käufe oder Verkäufe von Stammaktien gemeldet, und die Transaktion wird als "A" (Erwerb) klassifiziert. Das Dokument wurde am 30. Juni 2025 unterzeichnet.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine option grant; aligns CEO incentives, but limited immediate share-count impact—neutral for valuation.

This filing represents a standard executive compensation award rather than an open-market purchase or sale. The grant size (110,630 options) is modest relative to Incyte’s ~225 million shares outstanding and therefore does not meaningfully dilute shareholders. The $70.81 strike price appears set near prevailing market levels, indicating the award’s value depends on future performance. Because no common shares changed hands, near-term supply–demand dynamics remain unaffected. Overall, the disclosure is non-market-moving and is best viewed as routine alignment of management interests with shareholders.

TL;DR: Standard Section 16 filing; option grant follows typical four-year vesting—no governance red flags detected.

The Form 4 demonstrates timely compliance with Section 16 reporting requirements. Vesting over 48 months (25 % cliff plus monthly vesting) follows common practice, encouraging long-term value creation. The single-signatory structure confirms individual responsibility, and no 10b5-1 plan was referenced. Absent any accompanying stock sales, the filing does not suggest insider pessimism. While transparency is positive, the event is inherently not impactful to corporate governance risk assessments.

Il 26 giugno 2025, Incyte Corporation (NASDAQ: INCY) ha presentato un Modulo 4 che riporta una transazione interna da parte del Amministratore Delegato e Direttore William Meury. Il documento rivela una concessione di 110.630 opzioni su azioni per dipendenti con un prezzo di esercizio di 70,81 $ per azione. Le opzioni maturano il 25% dopo un anno, mentre il restante 75% matura in rate mensili uguali nei successivi tre anni, e scadono il 25 giugno 2035. Dopo questa concessione, Meury detiene beneficiariamente 110.630 titoli derivati, posseduti direttamente. Non sono stati segnalati acquisti o vendite di azioni ordinarie, e la transazione è classificata come "A" (acquisizione). Il documento è stato firmato il 30 giugno 2025.

El 26 de junio de 2025, Incyte Corporation (NASDAQ: INCY) presentó un Formulario 4 reportando una transacción interna por parte del Director Ejecutivo y Director William Meury. El informe revela una concesión de 110,630 opciones sobre acciones para empleados con un precio de ejercicio de $70.81 por acción. Las opciones se consolidan en un 25% después de un año, y el 75% restante se consolida en cuotas mensuales iguales durante los siguientes tres años, y expiran el 25 de junio de 2035. Tras esta concesión, Meury posee beneficiosamente 110,630 valores derivados, mantenidos directamente. No se reportaron compras ni ventas de acciones comunes, y la transacción se clasifica como "A" (adquisición). El documento fue firmado el 30 de junio de 2025.

2025� 6� 26�, 인사이트 코퍼레이�(NASDAQ: INCY)은 최고경영� � 이사 윌리� 뮤리� 내부� 거래� 보고하는 Form 4� 제출했습니다. 해당 보고서에� 주당 $70.81� 행사 가격으� 110,630개의 직원 주식매수선택� 부여가 공개되어 있습니다. � 옵션은 1� � 25%가 권리 취득되며, 나머지 75%� 이후 3년간 매월 균등하게 권리 취득되고, 2035� 6� 25�� 만료됩니�. 이번 부� 이후 뮤리� 직접 보유� 110,630개의 파생 증권� 실질 소유하게 됩니�. 보통� 매매� 보고되지 않았으며, 거래� "A"(취득)� 분류되었습니�. 문서� 2025� 6� 30일에 서명되었습니�.

Le 26 juin 2025, Incyte Corporation (NASDAQ : INCY) a déposé un formulaire 4 rapportant une transaction d’initié réalisée par le Directeur Général et Administrateur William Meury. Le document révèle l’attribution de 110 630 options d’achat d’actions pour les employés avec un prix d’exercice de 70,81 $ par action. Les options acquièrent 25 % de leurs droits après un an, le reste des 75 % étant acquis par mensualités égales sur les trois années suivantes, et expirent le 25 juin 2035. Après cette attribution, Meury détient de manière bénéficiaire 110 630 titres dérivés, détenus directement. Aucune acquisition ou vente d’actions ordinaires n’a été signalée, et la transaction est classée « A » (acquisition). Le document a été signé le 30 juin 2025.

Am 26. Juni 2025 reichte die Incyte Corporation (NASDAQ: INCY) ein Formular 4 ein, das eine Insider-Transaktion des Vorstandsvorsitzenden und Direktors William Meury meldet. Die Einreichung offenbart die Gewährung von 110.630 Mitarbeiteraktienoptionen mit einem Ausübungspreis von 70,81 $ pro Aktie. Die Optionen werden zu 25 % nach einem Jahr fällig, die restlichen 75 % werden in gleichen monatlichen Raten über die folgenden drei Jahre fällig und verfallen am 25. Juni 2035. Nach dieser Gewährung besitzt Meury wirtschaftlich 110.630 derivative Wertpapiere, die direkt gehalten werden. Es wurden keine Käufe oder Verkäufe von Stammaktien gemeldet, und die Transaktion wird als "A" (Erwerb) klassifiziert. Das Dokument wurde am 30. Juni 2025 unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Meury William

(Last) (First) (Middle)
1801 AUGUSTINE CUT-OFF

(Street)
WILMINGTON DE 19803

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
INCYTE CORP [ INCY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) X Other (specify below)
Chief Executive Officer President
3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $70.81 06/26/2025 A 110,630 (1) 06/25/2035 Common Stock 110,630 $0 110,630 D
Explanation of Responses:
1. The June 26, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
Remarks:
/s/ Elizabeth Feeney, Attorney-In-Fact 06/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Incyte (INCY) report on 26 June 2025?

The company granted 110,630 employee stock options to CEO William Meury.

What is the exercise price of the newly granted INCY options?

The exercise price is $70.81 per share.

How do the options vest for Incyte CEO William Meury?

They vest 25 % after one year, with the remaining shares vesting monthly over the next three years.

When do the Incyte stock options granted to the CEO expire?

The options expire on 25 June 2035.

Did the Form 4 report any sale or purchase of Incyte common stock?

No. The filing only reports an option grant; no common shares were bought or sold.
Incyte Corp

NASDAQ:INCY

INCY Rankings

INCY Latest News

INCY Latest SEC Filings

INCY Stock Data

13.71B
188.92M
1.99%
96.76%
3.02%
Biotechnology
Services-commercial Physical & Biological Research
United States
WILMINGTON